NasdaqGM - Nasdaq Real Time Price USD

MannKind Corporation (MNKD)

4.5900 0.0000 (0.00%)
At close: May 17 at 4:00 PM EDT
Currency in USD All numbers in thousands
Download
Breakdown
TTM
12/31/2023
12/31/2022
12/31/2021
12/31/2020
Total Revenue
224,599.0000
198,962.0000
99,770.0000
75,442.0000
65,144.0000
Cost of Revenue
65,156.0000
62,771.0000
57,497.0000
38,857.0000
24,641.0000
Gross Profit
159,443.0000
136,191.0000
42,273.0000
36,585.0000
40,503.0000
Operating Expense
128,482.0000
125,597.0000
111,194.0000
90,068.0000
65,288.0000
Operating Income
30,961.0000
10,594.0000
-68,921.0000
-53,483.0000
-24,785.0000
Net Non Operating Interest Income Expense
-20,927.0000
-19,007.0000
-22,256.0000
-16,465.0000
-9,304.0000
Other Income Expense
278.0000
-1,964.0000
3,777.0000
-10,978.0000
-23,369.0000
Pretax Income
10,312.0000
-10,377.0000
-87,400.0000
-80,926.0000
-57,458.0000
Tax Provision
1,825.0000
1,561.0000
--
--
-218.0000
Net Income Common Stockholders
8,487.0000
-11,938.0000
-87,400.0000
-80,926.0000
-57,240.0000
Diluted NI Available to Com Stockholders
8,487.0000
-11,938.0000
-87,400.0000
-80,926.0000
-57,240.0000
Basic EPS
0.04
-0.04
-0.34
-0.32
-0.26
Diluted EPS
0.04
-0.04
-0.34
-0.32
-0.26
Basic Average Shares
268,610.7500
267,014.0000
257,092.0000
249,244.0000
222,585.0000
Diluted Average Shares
282,205.0000
267,014.0000
257,092.0000
249,244.0000
222,585.0000
Total Operating Income as Reported
31,398.0000
8,678.0000
-64,110.0000
-47,022.0000
-47,913.0000
Total Expenses
193,638.0000
188,368.0000
168,691.0000
128,925.0000
89,929.0000
Net Income from Continuing & Discontinued Operation
8,487.0000
-11,938.0000
-87,400.0000
-80,926.0000
-57,240.0000
Normalized Income
8,267.2532
-10,290.0600
-91,279.0000
-70,187.0000
-33,941.5680
Interest Income
8,286.0000
6,154.0000
2,513.0000
112.0000
167.0000
Interest Expense
29,213.0000
25,161.0000
24,769.0000
16,577.0000
9,471.0000
Net Interest Income
-20,927.0000
-19,007.0000
-22,256.0000
-16,465.0000
-9,304.0000
EBIT
39,525.0000
14,784.0000
-62,631.0000
-64,349.0000
-47,987.0000
EBITDA
45,654.0000
20,620.0000
-56,319.0000
-61,105.0000
-44,661.0000
Reconciled Cost of Revenue
65,156.0000
62,771.0000
57,497.0000
38,857.0000
24,641.0000
Reconciled Depreciation
6,129.0000
5,836.0000
6,312.0000
3,244.0000
3,326.0000
Net Income from Continuing Operation Net Minority Interest
8,487.0000
-11,938.0000
-87,400.0000
-80,926.0000
-57,240.0000
Total Unusual Items Excluding Goodwill
267.0000
-2,086.0000
3,879.0000
-10,739.0000
-23,392.0000
Total Unusual Items
267.0000
-2,086.0000
3,879.0000
-10,739.0000
-23,392.0000
Normalized EBITDA
45,387.0000
22,706.0000
-60,198.0000
-50,366.0000
-21,269.0000
Tax Rate for Calcs
0.0002
0.0002
--
--
0.0000
Tax Effect of Unusual Items
47.2532
-438.0600
--
--
-93.5680
12/31/2020 - 7/28/2004

Upgrade to begin using 40 years of financial statements and get so much more.

Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.

Upgrade

Related Tickers

UTHR United Therapeutics Corporation
274.26
+0.75%
 
LQDA Liquidia Corporation
12.71
-0.24%
 
GERN Geron Corporation
3.8100
-2.31%
 
DTIL Precision BioSciences, Inc.
12.40
+3.51%
 
NRXP NRx Pharmaceuticals, Inc.
3.5400
+0.57%
 
ALT Altimmune, Inc.
8.01
-10.00%
 
BCRX BioCryst Pharmaceuticals, Inc.
6.29
-2.86%
 
AUPH Aurinia Pharmaceuticals Inc.
5.76
-0.17%
 
RVPH Reviva Pharmaceuticals Holdings, Inc.
1.6700
-2.34%
 
VSTM Verastem, Inc.
11.50
-5.19%